Adheron Therapeutics

San Francisco, United States Founded: 2006 • Age: 20 yrs Acquired By Roche
Disrupting cell adhesion to treat a variety of diseases

About Adheron Therapeutics

Adheron Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2006 by David Lee and Michael Brenner, and was acquired by Roche in October 2015. Disrupting cell adhesion to treat a variety of diseases. Adheron Therapeutics has raised $1.5 million across 1 funding round from investors including Roche. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Adheron Therapeutics Inc. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.

Company details

Adheron is a company focused on leveraging pioneering technology that disrupts cell adhesion to treat a varietyof diseases. Adheron Therapeutics has developed a pioneering technology that disrupts immune cell adhesion through a cell surface protein called Cadherin-11 in order to develop potential treatments for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic diseases. The lead asset, SDP051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase 1 of clinical development. Adheron announced on October 9, 2015 that they have agreed to be acquired by Roche

  • Headquarters San Francisco, United States
  • Founders David Lee, Michael Brenner
  • Stage Acquired
  • Sectors
    Healthcare
  • Website adherontherapeutics.com
  • Social LinkedIn
  • Acquired by Roche (Oct 2015)
  • Legal Name Adheron Therapeutics Inc
Key Metrics
  • Total Equity Funding
    $1.5M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.5M (USD), Seed

    Jul 2015

  • Investors
  • Acquired by
    Roche

    (Oct 2015)

Funding Insights of Adheron Therapeutics

Adheron Therapeutics has successfully raised a total of $1.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.5 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.5M
  • Total Rounds 1
  • Last Round Seed β€” $1.5M
  • First Round $1.5M

    (Jul 2015)

All 1 funding rounds of Adheron Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2015$1.5MSeed––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Adheron Therapeutics

Adheron Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Pharmaceuticals and diagnostics kits are developed for various diseases.
1896roche.comBasel, Switzerland
Premium access

Investor details for Adheron Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Adheron Therapeutics

2 people are tracked at Adheron Therapeutics (2 in leadership).

NameRoleGroup
David Lee
Co-FounderLeadership
Michael Brenner
Co-FounderLeadership
Premium access

Complete people profiles for Adheron Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Adheron Therapeutics

3 dated milestones of Adheron Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Adheron Therapeutics is founded.
  2. Funding First funding round of $1.5M.
  3. Exit Acquired by Roche.

Competitors of Adheron Therapeutics

Adheron Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
biogen.com1978Cambridge, United States$80M1
Therapies for neurodegenerative and immunology disorders are developed.
kymeratx.com2016Cambridge, United States$197M150
Small molecule protein degraders are developed for various disorders.
puretechhealth.com2001Boston, United States$107M171
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Premium access

Detailed competitors of Adheron Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Adheron Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Adheron Therapeutics

Adheron Therapeutics was founded in 2006 and raised its 1st funding round 9 years after it was founded.

Adheron Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Adheron Therapeutics is a funded company, having raised a total of $1.5M across 1 funding round to date. The company's 1st funding round was a Seed of $1.5M, raised on Jul 2015.

Adheron is a company focused on leveraging pioneering technology that disrupts cell adhesion to treat a varietyof diseases. Adheron Therapeutics has developed a pioneering technology that disrupts immune cell adhesion through a cell surface protein called Cadherin-11 in order to develop potential treatments for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic diseases. The lead asset, SDP051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase 1 of clinical development. Adheron announced on October 9, 2015 that they have agreed to be acquired by Roche.

Adheron Therapeutics's top competitors include Kymeratx, PureTech Health and Biogen.

Adheron Therapeutics has 1 investor. Key investors include Roche.

Adheron Therapeutics operates through Adheron Therapeutics Inc.

Yes. Adheron Therapeutics was acquired by Roche in October 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available